The combined diagnostic value of 5-hmC and PRAME immunohistochemistry in melanocytic neoplasms
The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be...
Saved in:
Published in | Pathology, research and practice Vol. 270; p. 155993 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Germany
Elsevier GmbH
01.06.2025
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms. |
---|---|
AbstractList | The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms. The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms.The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology. 5-hydroxymethylcytosine (5-hmC) and PRAME (PReferentially expressed Antigen in MElanoma) are recent immunohistochemical markers which have been shown to be valuable in distinguishing benign from malignant melanocytic neoplasms. A retrospective cohort of 144 benign, borderline (Spitz nevi, atypical Spitz tumors and dysplastic nevi) and malignant melanocytic tumors at our institution were analyzed for 5-hmC and PRAME expression by immunohistochemistry. Compared to benign nevi, melanoma cases had higher PRAME expression (p < 0.0001) and lower 5-hmC (p < 0.0001) expression. In receiver operator curve analysis, 5-hmC and PRAME were good discriminators between benign and malignant neoplasms; the area under the curve (AUC) was 0.91 for 5-hmC (p < 0.0001) and 0.94 for PRAME (p < 0.001). Subgroup analysis showed that 5-hmC expression was significantly different between dysplastic nevi and melanoma. The combination of PRAME and 5-hmC significantly improved the predictive ability of these markers (AUC 0.97, p < 0.001). Having both PRAME expression of 4 + (> 75 % lesional cells positive) and 5-hmC of < 0.2 was highly specific for malignancy (98 %) with a sensitivity of 61 %. Utilizing 5-hmC and PRAME in conjunction improves their diagnostic value in distinguishing benign from malignant melanocytic neoplasms. |
ArticleNumber | 155993 |
Author | Kamil, Zaid Saeed Wood, Kimberly Ghazarian, Danny Yu, Yanhong Hosseini, Niloufar Dodington, David |
Author_xml | – sequence: 1 givenname: Yanhong surname: Yu fullname: Yu, Yanhong email: yanhong.yu@mail.utoronto.ca organization: University of Toronto, Toronto, ON, Canada – sequence: 2 givenname: Niloufar surname: Hosseini fullname: Hosseini, Niloufar organization: The Ottawa Hospital, Ottawa, ON, Canada – sequence: 3 givenname: David surname: Dodington fullname: Dodington, David organization: University of Toronto, Toronto, ON, Canada – sequence: 4 givenname: Kimberly surname: Wood fullname: Wood, Kimberly organization: University of Saskatchewan, Regina Pasqua Hospital, Regina, SK, Canada – sequence: 5 givenname: Danny surname: Ghazarian fullname: Ghazarian, Danny organization: University of Toronto, Toronto, ON, Canada – sequence: 6 givenname: Zaid Saeed surname: Kamil fullname: Kamil, Zaid Saeed organization: University of Toronto, Toronto, ON, Canada |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40328178$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kEtrGzEUhUVJqR_tD-gmaNnNOHqMZsZ0FYzTBhIagrut0Eh3apmRNJVmDP73kXHSZVYHLt-5nHMW6MoHDwh9pWRFCa1uDqshDitGmFhRIdZr_gHNaUWbglScXqE54WVZEM6bGVqkdCCE1KSkn9CsJJw1tG7m6M9uD1gH11oPBhur_vqQRqvxUfUT4NBhUezdBitv8NPz7eMWW-cmH_Y2jUHvwWWNJ2w9dtArH_TpbPYQhl4llz6jj53qE3x51SX6fbfdbX4WD79-3G9uHwrNST0WFW87Y2qjOgHQEACoOaGKlg2YThtdG2DMiLZat4LpygjRsbJudMd4a0Ruu0TfLn-HGP5NkEaZg2nocyQIU5KcEUqpqNcso9ev6NQ6MHKI1ql4km-bZIBeAB1DShG6_wgl8ry7POTLIM-7y8vu2fP94oFc8mghyqQteA3GRtCjNMG-434BLsKLXQ |
Cites_doi | 10.1111/cup.14245 10.1097/PAS.0000000000001393 10.18632/oncotarget.6062 10.1038/modpathol.2013.224 10.1016/j.jid.2016.07.015 10.1097/PAS.0000000000002032 10.1111/cup.13412 10.1186/s13000-022-01218-3 10.1111/cup.14290 10.1111/cup.14212 10.1097/PAS.0000000000001134 10.1097/CMR.0000000000000315 10.1002/mc.22638 10.1038/bjc.2016.187 10.1111/cup.14226 10.1016/j.humpath.2021.11.002 10.1016/j.jdermsci.2013.09.008 10.3390/jcm13061554 10.1111/cup.14267 10.1038/sj.bjc.6605880 10.1111/cup.13958 10.1111/cup.12564 10.1016/j.humpath.2021.12.008 10.1016/j.cell.2012.07.033 10.18632/oncotarget.316 10.1038/modpathol.2014.99 10.1016/j.labinv.2025.104123 10.1016/j.pathol.2022.05.012 10.1016/S1074-7613(00)80426-4 10.1038/modpathol.2016.159 10.1111/cup.12880 10.1371/journal.pone.0146302 10.3390/cancers13153864 |
ContentType | Journal Article |
Copyright | 2025 Crown Copyright © 2025. Published by Elsevier GmbH. All rights reserved. Copyright © 2025. Published by Elsevier GmbH. |
Copyright_xml | – notice: 2025 – notice: Crown Copyright © 2025. Published by Elsevier GmbH. All rights reserved. – notice: Copyright © 2025. Published by Elsevier GmbH. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.prp.2025.155993 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1618-0631 |
ExternalDocumentID | 40328178 10_1016_j_prp_2025_155993 S0344033825001852 |
Genre | Journal Article |
GroupedDBID | --- --K --M .55 .GJ .~1 0R~ 123 1B1 1~. 1~5 29O 3O- 4.4 457 4CK 4G. 53G 5RE 5VS 7-5 71M 7X7 88E 88I 8AF 8FE 8FH 8FI 8FJ 8G5 8P~ 8R4 8R5 9JM AABNK AAEDT AAEDW AAIKJ AAKOC AAKPP AALRI AAOAW AAQFI AAQXK AATTM AAXKI AAXUO AAYWO ABBQC ABFNM ABGSF ABLJU ABMAC ABMZM ABUDA ABUWG ABWVN ABXDB ACDAQ ACGFO ACGFS ACGOD ACPRK ACRLP ACRPL ACVFH ADBBV ADCNI ADEZE ADKUU ADMUD ADNMO ADUVX AEBSH AEHWI AEIPS AEKER AENEX AEUPX AFJKZ AFKRA AFPUW AFTJW AGCQF AGHFR AGQPQ AGRDE AGRNS AGUBO AGYEJ AHHHB AHMBA AIEXJ AIGII AIIUN AIKHN AITUG AJRQY AKBMS AKRWK AKYEP ALIPV ALMA_UNASSIGNED_HOLDINGS AMRAJ ANKPU ANZVX ASPBG AVWKF AXJTR AZFZN AZQEC BBNVY BCR BCU BEC BENPR BHPHI BKOJK BLC BLXMC BNPGV BPHCQ BVXVI CAG CCPQU COF CS3 DU5 DWQXO EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GNUQQ GUQSH HCIFZ HMCUK HVGLF HZ~ IHE J1W K-O KOM L7B LK8 M1P M2O M2P M2Q M41 M7P MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PADUT PC. PEA PHGZM PHGZT PQQKQ PRG PROAC PSQYO Q2X Q38 R2- RIG ROL RPZ S0X SDF SDG SES SEW SJFOW SSU SSZ T5I T5J T5K UDS UKHRP X7M ZGI ZXP ~G- AAYXX ACIEU CITATION AFXIZ CGR CUY CVF ECM EFKBS EIF NPM PJZUB PPXIY PQGLB 7X8 |
ID | FETCH-LOGICAL-c307t-63bfdd7daf5ee80eee7301a148edfcdc7de22d5b69b52c6d55f2478cf23bd5063 |
IEDL.DBID | .~1 |
ISSN | 0344-0338 1618-0631 |
IngestDate | Fri Jul 11 18:20:19 EDT 2025 Mon Jul 21 05:50:24 EDT 2025 Tue Jul 01 04:42:10 EDT 2025 Sat Jun 14 16:51:21 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Keywords | Immunohistochemistry PReferentially expressed Antigen in MElanoma 5-hydroxymethylcytosine Melanoma Nevus |
Language | English |
License | Crown Copyright © 2025. Published by Elsevier GmbH. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c307t-63bfdd7daf5ee80eee7301a148edfcdc7de22d5b69b52c6d55f2478cf23bd5063 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 40328178 |
PQID | 3201115792 |
PQPubID | 23479 |
ParticipantIDs | proquest_miscellaneous_3201115792 pubmed_primary_40328178 crossref_primary_10_1016_j_prp_2025_155993 elsevier_sciencedirect_doi_10_1016_j_prp_2025_155993 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2025-06-01 |
PublicationDateYYYYMMDD | 2025-06-01 |
PublicationDate_xml | – month: 06 year: 2025 text: 2025-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Germany |
PublicationPlace_xml | – name: Germany |
PublicationTitle | Pathology, research and practice |
PublicationTitleAlternate | Pathol Res Pract |
PublicationYear | 2025 |
Publisher | Elsevier GmbH |
Publisher_xml | – name: Elsevier GmbH |
References | Gassenmaier (bib27) Jul 31 2021; 13 Kim (bib24) Apr 28 2022; 17 Larson (bib12) Jul 2014; 27 Fang (bib28) Feb 28 2025; 105 Lee (bib15) Mar 2017; 44 Rothrock (bib20) Oct 2022; 49 Parra, Linos, Li, Yan (bib23) Jul 2022; 49 Ricci (bib26) May 01 2023; 47 Rodić, Zampella, Sharma, Burns, Taube (bib8) Nov 2015; 42 Rawson (bib17) Dec 2022; 54 Koh, Lau, Scapa, Cassarino (bib22) Aug 2022; 49 Lezcano, Pulitzer, Moy, Hollmann, Jungbluth, Busam (bib4) Apr 2020; 44 Uchiyama (bib9) Feb 2014; 73 Benešová (bib33) Aug 2017; 56 Lezcano, Jungbluth, Nehal, Hollmann, Busam (bib2) Nov 2018; 42 Lee (bib13) Feb 2015; 28 Haffner (bib11) Aug 2011; 2 Ikeda (bib1) Feb 1997; 6 Lohman, Steen, Grekin, North (bib6) Jul 2021; 48 O'Connor, Dai, Fraga (bib21) Sep 2022; 49 Saldanha (bib16) Jan 2017; 30 Kaczorowski, Lasota, Dudek, Małkiewicz, Miettinen, Hałoń (bib29) Mar 08 2024; 13 Pavlova, Fraitag, Hohl (bib10) Dec 2016; 136 Siref, Huynh, Balzer, Frishberg, Essner, Shon (bib14) Apr 2019; 46 Munari (bib34) 2016; 11 Lian (bib7) Sep 14 2012; 150 Olds, Utz, Abrams, Terrano, Mehregan (bib5) Jun 2022; 49 Lee (bib19) Nov 10 2015; 6 Almstrup (bib30) Oct 12 2010; 103 Hu (bib25) Feb 2022; 120 Orsatti (bib31) Sep 2022; 237 Fattori, de la Fouchardière, Cribier, Mitcov (bib3) Mar 2022; 121 Nettersheim (bib32) Aug 09 2016; 115 Micevic, Theodosakis, Taube, Bosenberg, Rodić (bib18) Apr 2017; 27 Saldanha (10.1016/j.prp.2025.155993_bib16) 2017; 30 Haffner (10.1016/j.prp.2025.155993_bib11) 2011; 2 Olds (10.1016/j.prp.2025.155993_bib5) 2022; 49 Gassenmaier (10.1016/j.prp.2025.155993_bib27) 2021; 13 Koh (10.1016/j.prp.2025.155993_bib22) 2022; 49 Hu (10.1016/j.prp.2025.155993_bib25) 2022; 120 Rawson (10.1016/j.prp.2025.155993_bib17) 2022; 54 Nettersheim (10.1016/j.prp.2025.155993_bib32) 2016; 115 Micevic (10.1016/j.prp.2025.155993_bib18) 2017; 27 Lezcano (10.1016/j.prp.2025.155993_bib4) 2020; 44 Lee (10.1016/j.prp.2025.155993_bib15) 2017; 44 Lian (10.1016/j.prp.2025.155993_bib7) 2012; 150 Fang (10.1016/j.prp.2025.155993_bib28) 2025; 105 Lezcano (10.1016/j.prp.2025.155993_bib2) 2018; 42 Rodić (10.1016/j.prp.2025.155993_bib8) 2015; 42 O'Connor (10.1016/j.prp.2025.155993_bib21) 2022; 49 Benešová (10.1016/j.prp.2025.155993_bib33) 2017; 56 Fattori (10.1016/j.prp.2025.155993_bib3) 2022; 121 Ikeda (10.1016/j.prp.2025.155993_bib1) 1997; 6 Pavlova (10.1016/j.prp.2025.155993_bib10) 2016; 136 Orsatti (10.1016/j.prp.2025.155993_bib31) 2022; 237 Lohman (10.1016/j.prp.2025.155993_bib6) 2021; 48 Munari (10.1016/j.prp.2025.155993_bib34) 2016; 11 Lee (10.1016/j.prp.2025.155993_bib19) 2015; 6 Larson (10.1016/j.prp.2025.155993_bib12) 2014; 27 Rothrock (10.1016/j.prp.2025.155993_bib20) 2022; 49 Ricci (10.1016/j.prp.2025.155993_bib26) 2023; 47 Uchiyama (10.1016/j.prp.2025.155993_bib9) 2014; 73 Siref (10.1016/j.prp.2025.155993_bib14) 2019; 46 Kim (10.1016/j.prp.2025.155993_bib24) 2022; 17 Kaczorowski (10.1016/j.prp.2025.155993_bib29) 2024; 13 Almstrup (10.1016/j.prp.2025.155993_bib30) 2010; 103 Lee (10.1016/j.prp.2025.155993_bib13) 2015; 28 Parra (10.1016/j.prp.2025.155993_bib23) 2022; 49 |
References_xml | – volume: 28 start-page: 218 year: Feb 2015 end-page: 229 ident: bib13 article-title: 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies publication-title: Mod. Pathol. – volume: 237 year: Sep 2022 ident: bib31 article-title: SOX2 and PRAME in the reprogramming of seminoma cells publication-title: Pathol. Res Pr. – volume: 13 year: Mar 08 2024 ident: bib29 article-title: Expression of immunotherapy target PRAME in cancer correlates with histone H3 acetylation and is unrelated to expression of methylating (DMNT3A/3B) and demethylating (TET1) enzymes publication-title: J. Clin. Med. – volume: 120 start-page: 9 year: Feb 2022 end-page: 17 ident: bib25 article-title: Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi publication-title: Hum. Pathol. – volume: 49 start-page: 709 year: Aug 2022 end-page: 716 ident: bib22 article-title: PRAME immunohistochemistry of spitzoid neoplasms publication-title: J. Cutan. Pathol. – volume: 42 start-page: 807 year: Nov 2015 end-page: 814 ident: bib8 article-title: Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations publication-title: J. Cutan. Pathol. – volume: 44 start-page: 249 year: Mar 2017 end-page: 255 ident: bib15 article-title: 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms publication-title: J. Cutan. Pathol. – volume: 30 start-page: 60 year: Jan 2017 end-page: 68 ident: bib16 article-title: 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma publication-title: Mod. Pathol. – volume: 105 year: Feb 28 2025 ident: bib28 article-title: PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation publication-title: Lab Invest – volume: 56 start-page: 1837 year: Aug 2017 end-page: 1850 ident: bib33 article-title: Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation publication-title: Mol. Carcinog. – volume: 6 start-page: 199 year: Feb 1997 end-page: 208 ident: bib1 article-title: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor publication-title: Immunity – volume: 49 start-page: 780 year: Sep 2022 end-page: 786 ident: bib21 article-title: PRAME immunohistochemistry for melanoma diagnosis: a STARD-compliant diagnostic accuracy study, (in eng) publication-title: J. Cutan. Pathol. – volume: 48 start-page: 856 year: Jul 2021 end-page: 862 ident: bib6 article-title: The utility of PRAME staining in identifying malignant transformation of melanocytic nevi publication-title: J. Cutan. Pathol. – volume: 11 year: 2016 ident: bib34 article-title: Global 5-hydroxymethylcytosine levels are profoundly reduced in multiple genitourinary malignancies publication-title: PLoS One – volume: 46 start-page: 261 year: Apr 2019 end-page: 266 ident: bib14 article-title: Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: an effective first-line test for the workup of sentinel lymph node specimen publication-title: J. Cutan. Pathol. – volume: 121 start-page: 19 year: Mar 2022 end-page: 28 ident: bib3 article-title: Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation publication-title: Hum. Pathol. – volume: 136 start-page: 2453 year: Dec 2016 end-page: 2461 ident: bib10 article-title: 5-Hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma publication-title: J. Invest Dermatol. – volume: 115 start-page: 454 year: Aug 09 2016 end-page: 464 ident: bib32 article-title: The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas publication-title: Br. J. Cancer – volume: 6 start-page: 37995 year: Nov 10 2015 end-page: 38004 ident: bib19 article-title: Loss of the epigenetic mark, 5-hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma publication-title: Oncotarget – volume: 17 start-page: 41 year: Apr 28 2022 ident: bib24 article-title: Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit publication-title: Diagn. Pathol. – volume: 54 start-page: 863 year: Dec 2022 end-page: 873 ident: bib17 article-title: Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics publication-title: Pathology – volume: 103 start-page: 1269 year: Oct 12 2010 end-page: 1276 ident: bib30 article-title: Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells publication-title: Br. J. Cancer – volume: 44 start-page: 503 year: Apr 2020 end-page: 508 ident: bib4 article-title: Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma publication-title: Am. J. Surg. Pathol. – volume: 150 start-page: 1135 year: Sep 14 2012 end-page: 1146 ident: bib7 article-title: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma publication-title: Cell – volume: 27 start-page: 936 year: Jul 2014 end-page: 944 ident: bib12 article-title: Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors publication-title: Mod. Pathol. – volume: 49 start-page: 510 year: Jun 2022 end-page: 514 ident: bib5 article-title: Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions publication-title: J. Cutan. Pathol. – volume: 49 start-page: 859 year: Oct 2022 end-page: 867 ident: bib20 article-title: Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions publication-title: J. Cutan. Pathol. – volume: 42 start-page: 1456 year: Nov 2018 end-page: 1465 ident: bib2 article-title: PRAME expression in melanocytic tumors publication-title: Am. J. Surg. Pathol. – volume: 49 start-page: 610 year: Jul 2022 end-page: 617 ident: bib23 article-title: PRAME expression in melanocytic lesions of the nail publication-title: J. Cutan. Pathol. – volume: 13 year: Jul 31 2021 ident: bib27 article-title: Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas publication-title: Cancers (Basel) – volume: 2 start-page: 627 year: Aug 2011 end-page: 637 ident: bib11 article-title: Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers publication-title: Oncotarget – volume: 73 start-page: 161 year: Feb 2014 end-page: 163 ident: bib9 article-title: 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi publication-title: J. Dermatol. Sci. – volume: 27 start-page: 85 year: Apr 2017 end-page: 96 ident: bib18 article-title: Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas publication-title: Melanoma Res – volume: 47 start-page: 599 year: May 01 2023 end-page: 610 ident: bib26 article-title: PRAME expression in mucosal melanoma of the head and neck region publication-title: Am. J. Surg. Pathol. – volume: 49 start-page: 709 issue: 8 year: 2022 ident: 10.1016/j.prp.2025.155993_bib22 article-title: PRAME immunohistochemistry of spitzoid neoplasms publication-title: J. Cutan. Pathol. doi: 10.1111/cup.14245 – volume: 44 start-page: 503 issue: 4 year: 2020 ident: 10.1016/j.prp.2025.155993_bib4 article-title: Immunohistochemistry for PRAME in the distinction of nodal nevi from metastatic melanoma publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0000000000001393 – volume: 6 start-page: 37995 issue: 35 year: 2015 ident: 10.1016/j.prp.2025.155993_bib19 article-title: Loss of the epigenetic mark, 5-hydroxymethylcytosine, correlates with small cell/nevoid subpopulations and assists in microstaging of human melanoma publication-title: Oncotarget doi: 10.18632/oncotarget.6062 – volume: 27 start-page: 936 issue: 7 year: 2014 ident: 10.1016/j.prp.2025.155993_bib12 article-title: Loss of 5-hydroxymethylcytosine correlates with increasing morphologic dysplasia in melanocytic tumors publication-title: Mod. Pathol. doi: 10.1038/modpathol.2013.224 – volume: 136 start-page: 2453 issue: 12 year: 2016 ident: 10.1016/j.prp.2025.155993_bib10 article-title: 5-Hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma publication-title: J. Invest Dermatol. doi: 10.1016/j.jid.2016.07.015 – volume: 47 start-page: 599 issue: 5 year: 2023 ident: 10.1016/j.prp.2025.155993_bib26 article-title: PRAME expression in mucosal melanoma of the head and neck region publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0000000000002032 – volume: 46 start-page: 261 issue: 4 year: 2019 ident: 10.1016/j.prp.2025.155993_bib14 article-title: Diagnostic utility of dual 5-hydroxymethylcytosine/Melan-A immunohistochemistry in differentiating nodal nevus from metastatic melanoma: an effective first-line test for the workup of sentinel lymph node specimen publication-title: J. Cutan. Pathol. doi: 10.1111/cup.13412 – volume: 17 start-page: 41 issue: 1 year: 2022 ident: 10.1016/j.prp.2025.155993_bib24 article-title: Cyclin D1 and PRAME expression in distinguishing melanoma in situ from benign melanocytic proliferation of the nail unit publication-title: Diagn. Pathol. doi: 10.1186/s13000-022-01218-3 – volume: 49 start-page: 859 issue: 10 year: 2022 ident: 10.1016/j.prp.2025.155993_bib20 article-title: Diagnostic utility of PRAME expression by immunohistochemistry in subungual and non-subungual acral melanocytic lesions publication-title: J. Cutan. Pathol. doi: 10.1111/cup.14290 – volume: 49 start-page: 510 issue: 6 year: 2022 ident: 10.1016/j.prp.2025.155993_bib5 article-title: Use of PRAME immunostaining to distinguish early melanoma in situ from benign pigmented conditions publication-title: J. Cutan. Pathol. doi: 10.1111/cup.14212 – volume: 42 start-page: 1456 issue: 11 year: 2018 ident: 10.1016/j.prp.2025.155993_bib2 article-title: PRAME expression in melanocytic tumors publication-title: Am. J. Surg. Pathol. doi: 10.1097/PAS.0000000000001134 – volume: 27 start-page: 85 issue: 2 year: 2017 ident: 10.1016/j.prp.2025.155993_bib18 article-title: Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas publication-title: Melanoma Res doi: 10.1097/CMR.0000000000000315 – volume: 56 start-page: 1837 issue: 8 year: 2017 ident: 10.1016/j.prp.2025.155993_bib33 article-title: Overexpression of TET dioxygenases in seminomas associates with low levels of DNA methylation and hydroxymethylation publication-title: Mol. Carcinog. doi: 10.1002/mc.22638 – volume: 115 start-page: 454 issue: 4 year: 2016 ident: 10.1016/j.prp.2025.155993_bib32 article-title: The cancer/testis-antigen PRAME supports the pluripotency network and represses somatic and germ cell differentiation programs in seminomas publication-title: Br. J. Cancer doi: 10.1038/bjc.2016.187 – volume: 49 start-page: 610 issue: 7 year: 2022 ident: 10.1016/j.prp.2025.155993_bib23 article-title: PRAME expression in melanocytic lesions of the nail publication-title: J. Cutan. Pathol. doi: 10.1111/cup.14226 – volume: 120 start-page: 9 year: 2022 ident: 10.1016/j.prp.2025.155993_bib25 article-title: Preferentially expressed antigen in melanoma immunohistochemistry as an adjunct for differential diagnosis in acral lentiginous melanoma and acral nevi publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2021.11.002 – volume: 73 start-page: 161 issue: 2 year: 2014 ident: 10.1016/j.prp.2025.155993_bib9 article-title: 5-Hydroxymethylcytosine as a useful marker to differentiate between malignant melanomas and benign melanocytic nevi publication-title: J. Dermatol. Sci. doi: 10.1016/j.jdermsci.2013.09.008 – volume: 13 issue: 6 year: 2024 ident: 10.1016/j.prp.2025.155993_bib29 article-title: Expression of immunotherapy target PRAME in cancer correlates with histone H3 acetylation and is unrelated to expression of methylating (DMNT3A/3B) and demethylating (TET1) enzymes publication-title: J. Clin. Med. doi: 10.3390/jcm13061554 – volume: 49 start-page: 780 issue: 9 year: 2022 ident: 10.1016/j.prp.2025.155993_bib21 article-title: PRAME immunohistochemistry for melanoma diagnosis: a STARD-compliant diagnostic accuracy study, (in eng) publication-title: J. Cutan. Pathol. doi: 10.1111/cup.14267 – volume: 103 start-page: 1269 issue: 8 year: 2010 ident: 10.1016/j.prp.2025.155993_bib30 article-title: Carcinoma in situ testis displays permissive chromatin modifications similar to immature foetal germ cells publication-title: Br. J. Cancer doi: 10.1038/sj.bjc.6605880 – volume: 48 start-page: 856 issue: 7 year: 2021 ident: 10.1016/j.prp.2025.155993_bib6 article-title: The utility of PRAME staining in identifying malignant transformation of melanocytic nevi publication-title: J. Cutan. Pathol. doi: 10.1111/cup.13958 – volume: 42 start-page: 807 issue: 11 year: 2015 ident: 10.1016/j.prp.2025.155993_bib8 article-title: Diagnostic utility of 5-hydroxymethylcytosine immunohistochemistry in melanocytic proliferations publication-title: J. Cutan. Pathol. doi: 10.1111/cup.12564 – volume: 121 start-page: 19 year: 2022 ident: 10.1016/j.prp.2025.155993_bib3 article-title: Preferentially expressed Antigen in MElanoma immunohistochemistry as an adjunct for evaluating ambiguous melanocytic proliferation publication-title: Hum. Pathol. doi: 10.1016/j.humpath.2021.12.008 – volume: 150 start-page: 1135 issue: 6 year: 2012 ident: 10.1016/j.prp.2025.155993_bib7 article-title: Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma publication-title: Cell doi: 10.1016/j.cell.2012.07.033 – volume: 2 start-page: 627 issue: 8 year: 2011 ident: 10.1016/j.prp.2025.155993_bib11 article-title: Global 5-hydroxymethylcytosine content is significantly reduced in tissue stem/progenitor cell compartments and in human cancers publication-title: Oncotarget doi: 10.18632/oncotarget.316 – volume: 28 start-page: 218 issue: 2 year: 2015 ident: 10.1016/j.prp.2025.155993_bib13 article-title: 5-Hydroxymethylcytosine expression in metastatic melanoma versus nodal nevus in sentinel lymph node biopsies publication-title: Mod. Pathol. doi: 10.1038/modpathol.2014.99 – volume: 105 issue: 5 year: 2025 ident: 10.1016/j.prp.2025.155993_bib28 article-title: PRAME expression in melanoma is negatively regulated by TET2-mediated DNA hydroxymethylation publication-title: Lab Invest doi: 10.1016/j.labinv.2025.104123 – volume: 54 start-page: 863 issue: 7 year: 2022 ident: 10.1016/j.prp.2025.155993_bib17 article-title: Diagnostic utility of PRAME, p53 and 5-hmC immunostaining for distinguishing melanomas from naevi, neurofibromas, scars and other histological mimics publication-title: Pathology doi: 10.1016/j.pathol.2022.05.012 – volume: 6 start-page: 199 issue: 2 year: 1997 ident: 10.1016/j.prp.2025.155993_bib1 article-title: Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor publication-title: Immunity doi: 10.1016/S1074-7613(00)80426-4 – volume: 30 start-page: 60 issue: 1 year: 2017 ident: 10.1016/j.prp.2025.155993_bib16 article-title: 5-Hydroxymethylcytosine is an independent predictor of survival in malignant melanoma publication-title: Mod. Pathol. doi: 10.1038/modpathol.2016.159 – volume: 44 start-page: 249 issue: 3 year: 2017 ident: 10.1016/j.prp.2025.155993_bib15 article-title: 5-Hydroxymethylcytosine is a nuclear biomarker to assess biological potential in histologically ambiguous heavily pigmented melanocytic neoplasms publication-title: J. Cutan. Pathol. doi: 10.1111/cup.12880 – volume: 11 issue: 1 year: 2016 ident: 10.1016/j.prp.2025.155993_bib34 article-title: Global 5-hydroxymethylcytosine levels are profoundly reduced in multiple genitourinary malignancies publication-title: PLoS One doi: 10.1371/journal.pone.0146302 – volume: 237 year: 2022 ident: 10.1016/j.prp.2025.155993_bib31 article-title: SOX2 and PRAME in the reprogramming of seminoma cells publication-title: Pathol. Res Pr. – volume: 13 issue: 15 year: 2021 ident: 10.1016/j.prp.2025.155993_bib27 article-title: Diffuse PRAME expression is highly specific for thin melanomas in the distinction from severely dysplastic nevi but does not distinguish metastasizing from non-metastasizing thin melanomas publication-title: Cancers (Basel) doi: 10.3390/cancers13153864 |
SSID | ssj0007041 |
Score | 2.3940105 |
Snippet | The diagnosis of melanocytic neoplasms, particularly those with borderline morphologic features, remains a challenging area in dermatopathology.... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 155993 |
SubjectTerms | 5-hydroxymethylcytosine 5-Methylcytosine - analogs & derivatives Adolescent Adult Aged Antigens, Neoplasm - analysis Antigens, Neoplasm - metabolism Biomarkers, Tumor - analysis Diagnosis, Differential Dysplastic Nevus Syndrome - diagnosis Dysplastic Nevus Syndrome - metabolism Dysplastic Nevus Syndrome - pathology Female Humans Immunohistochemistry Male Melanoma Melanoma - diagnosis Melanoma - metabolism Melanoma - pathology Middle Aged Nevus Nevus, Epithelioid and Spindle Cell - diagnosis Nevus, Epithelioid and Spindle Cell - metabolism Nevus, Epithelioid and Spindle Cell - pathology PReferentially expressed Antigen in MElanoma Retrospective Studies Skin Neoplasms - diagnosis Skin Neoplasms - metabolism Skin Neoplasms - pathology Young Adult |
Title | The combined diagnostic value of 5-hmC and PRAME immunohistochemistry in melanocytic neoplasms |
URI | https://dx.doi.org/10.1016/j.prp.2025.155993 https://www.ncbi.nlm.nih.gov/pubmed/40328178 https://www.proquest.com/docview/3201115792 |
Volume | 270 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS8MwEA9DQXwRv50fI4JPQrcuTZr2cYyNqWyIOtiTpc0lOHHtcNuDL_7t5vqh-DAffGxIaPu75O7C_e6OkKskASZl6DtBwpWDgSEnDLjBrqlKGc6U8TDfeTjyB2N-OxGTGulWuTBIqyx1f6HTc21djrRKNFvz6bT1iMXqXHvDskbcxRRgzGDnEnd58_OH5iHdvHslTnZwdhXZzDle87xkJRNNDM6F3jrbtM73zG1Qf5fslM4j7RTft0dqOt0nW8MyPH5Anq3Qqf0Te9vVQKFg0dm5FEt6a5oZKpyXWZfGKdD7h86wR6eYHpLlRYdV1fqNTlM6029xmqkPXJwiyTxezBaHZNzvPXUHTtlAwVH26C4d30sMgITYCK0DV2uN5zm2NyANRoGSoBkDkfhhIpjyQQjDuAyUYV4CwjovR2QjzVJ9QmjY1gqkNe-xAq58E0phF4A2wBRTblAn1xV00byokxFVBLJXOzKPEOeowLlOeAVu9EvYkdXjfy27rAQRWUAwshFbCFaLyEM3pi1kyOrkuJDQ91dwrBjYlsHp_156RrbxqWCHnZON5ftKX1g_ZJk08o3WIJudm7vB6Atg8N1c |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1LT9wwEB5RKrW9VH13-6Cu1F4qhc06dpwcekA8tBQWVS1InGoSj60uYrOr7qKKS_8Uf5CZPEAc6AGJqxMn1ufRPDTfzAB8KkuUxuRplJXKRZwYivJMBZ6a6lxQ0oWE651He-nwQH071IdLcN7VwjCtstX9jU6vtXW70m_R7M_G4_5PblYXU4RFRjzmEuCWWbnjz_5S3Db_ur1Bl_xZyq3N_fVh1I4WiBwJ9SJKkzIgGiyC9j6Lvfcs6QXFBh6DQ2fQS4m6TPNSS5ei1kEqk7kgkxI1mXX67j24r0hd8NiE1X9XvBIT1-My-XQRH69LpdakslndI1PqVc4G5slNxvAmZ7c2eltP4HHrrYq1BpCnsOSrZ_Bg1Objn8MvkjJB0FF47VFgQ9ujdwX3EPdiGoSOfk_WRVGh-P5jbbQpxlyPMq27HLtu1pwYV2LiT4pq6s54c8Ws9mI-mb-AgzuB9SUsV9PKvwaRD7xDQ_5E4VC5NORG0wb0AaWTLs568KWDzs6axhy2Y6wd08rMMs62wbkHqgPXXpMuS4bjf9s-dhdhCRBOpRQEwencJuw3DbTJZQ9eNTd0eQrFLQoHJntzu59-gIfD_dGu3d3e23kLj_hJQ017B8uLP6f-PTlBi3KlFjoBR3ct5RcKPxt5 |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+combined+diagnostic+value+of+5-hmC+and+PRAME+immunohistochemistry+in+melanocytic+neoplasms&rft.jtitle=Pathology%2C+research+and+practice&rft.au=Yu%2C+Yanhong&rft.au=Hosseini%2C+Niloufar&rft.au=Dodington%2C+David&rft.au=Wood%2C+Kimberly&rft.date=2025-06-01&rft.issn=1618-0631&rft.eissn=1618-0631&rft.volume=270&rft.spage=155993&rft_id=info:doi/10.1016%2Fj.prp.2025.155993&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-0338&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-0338&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-0338&client=summon |